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OPEN
REVIEW
Interleukin-6: a new therapeutic target in systemic
sclerosis?
Steven O’Reilly, Rachel Cant, Marzena Ciechomska and Jacob M van Laar
Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a
wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells, except lymphocytes
and hepatocytes, express the functional membrane IL-6 receptor thus reducing the number of IL-6-responsive cells. Trans-
signalling, the shedding of the membrane-bound form of the IL-6 receptor into the local microenvironment, greatly increases
the range of cells that can respond. IL-6 has been demonstrated to have a pivotal role in the pathogenesis of rheumatoid
arthritis, Castleman’s disease and Crohn’s disease exemplified by the use of an anti-IL-6 biological therapy. However, IL-6 is
also associated with the autoimmune disease systemic sclerosis (SSc) and has been shown to be directly fibrotic. Elevated
levels of IL-6 are found in SSc patients and this correlates with skin thickness, suggesting a causal effect. This review focuses
on the role of IL-6 in SSc, a chronic autoimmune disease with fibrosis. In particular, we will examine the evidence base of the
role of IL-6 in fibrosis in this condition, especially the downstream effector pathways. We will then argue why molecular
targeting of IL-6 is a promising therapeutic target in this fibrosing disease.
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Systemic sclerosis (SSc) is a heterogeneous chronic disease that is
characterised by inflammation, vascular abnormalities and fibrosis of
skin and inner organs of unknown aetiology. The disease is very
heterogeneous and is broadly subdivided into limited and diffuse
forms and is autoimmune in nature. The limited form of SSc is more
mild and the diffuse form more aggressive, both subtypes have
inflammation and fibrosis as clinical features. Fibrosis is the end
point. Although great progress has been made in understanding the
pathogenesis of the disease, there is currently no specific treatment.
Raised acute phase proteins, such as C-reactive protein or interleukin-
6 (IL-6), in peripheral blood are typically observed in early phases of
the disease.1 These indicate that inflammation has a crucial role in the
early stages of the disease that could lead to fibrosis.
Evidence for the involvement of the immune system in SSc is clear
from studies demonstrating that in skin biopsies there are elevated
numbers of monocytes and T cells, and that these are found before
evidence of morphological fibrosis.2,3 Indeed, many of these
infiltrating immune cells are found perivascularly suggesting that
they have a role early in disease pathogenesis through the secretion of
cytokines that amplify and perpetuate the fibrosis. IL-6 is a classic
pro-inflammatory cytokine that is involved in the onset and
maintenance of multiple diseases, including rheumatoid arthritis
(RA),4 Castleman’s disease5 and osteoporosis.4 Furthermore, IL-6 is
central in various animal models of human autoimmune diseases,
including type II collagen-induced arthritis, where IL-6-knockout
(KO) mice are fully protected6 and also experimental autoimmune
encephalomyelitis is abrogated in IL-6-KO mice underscoring its
importance in autoimmune inflammatory conditions.7 In RA clinical
trials of tocilizumab, an anti-IL-6 receptor antibody has shown
therapeutic benefit. IL-6, however, has also been shown to have a
pivotal role in the pathogenesis of SSc in both human and animal
models, and high IL-6 levels have been reported in SSc.8 Increased
expression of IL-6 has been reported in the serum and skin of SSc
patients.8 The aim of this review is to discuss the role of IL-6 in SSc
and argue that it is a valid novel therapeutic target owing to recent
novel data in this area shedding light on its role.
IL-6
IL-6 is a pleiotropic cytokine that can be synthesised by a wide variety
of cells, and aberrant IL-6 signalling has been implicated in many
diseases.4 Many biological effects have been ascribed to IL-6, including
immunoregulation, T-cell differentiation, angiogenesis and osteoclast
formation. IL-6 has a molecular mass between 21–28 kDa depending
on glycosylation of the protein. IL-6 exhibits functional pleiotropy
and redundancy, and has a wide variety of effects depending on cell
context. It was initially discovered and called B-cell differentiation
factor because it was identified in tissue culture supernatants to
induce B cells to produce immunoglobulins.9,10 It is composed of four
main helices arranged in an up–up–down–down topology bundle. IL-
6R (CD126) is an IL-6 receptor that contains the ligand-binding site.
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Although IL-6R is sufficient for low-affinity binding, signal transduc-
tion requires the presence of the signalling molecule glycoprotein130
(gp130). This forms a functional signalling platform for which
downstream signalling occurs.
GP130 SIGNALLING
The gp130 system comprises a wide variety of ligands and receptors
that elicit a response by binding of ligands that all contain at least one
copy of the transmembrane protein gp130 by forming a hexameric
complex. The complex is comprised of a gp130 homodimer, together
with two ligands and two respective ligand-binding receptor
a-subunits. The expression of gp130 is ubiquitous. Mice that have
been genetically altered to overexpress gp130 develop multiple
haematopoietic abnormalities, including an expansion of immature
and committed progenitor cells in the bone marrow and spleen
resulting in lymphadenopathy.11 The gp130 signalling subunit is a
common shared subunit utilised by multiple cytokines, including IL-
6, and use of this common subunit induces redundancy of cytokines.
Although these cytokines share the common gp130 subunit to signal
and while many of the cytokines have redundant functions they exert
non-redundant functions as well. There are a family of gp130
cytokines that include IL-6, IL-11, leukaemia inhibitory factor,
oncostatin M, ciliary neurotrophic factor cardiotrophin-1,
cardiotrophin-like cytokine, IL-27 and IL-31.12
IL-6 SIGNALLING
IL-6 signalling commences when the soluble IL-6 binds to IL-6R
(CD126), which dimerises with the common subunit gp130. It is
important to note that while gp130 might be expressed widely in
isolation it cannot transduce a signal without a receptor, and this
signalling can be determined by the relative abundance of the
receptor. Downstream signalling occurs through Janus kinases
(JAK1 and JAK2), subsequent phosphorylation of the receptor sub
unit and activation of signal transducers and activators of transcrip-
tion 1 and 3 (STATs1/3),13 and also the RAS/Raf/MAPK and also the
PI-3 kinase pathway. Once STATs are activated it induces their
dimerisation, nuclear accumulation and binding to DNA. STATs
regulate a variety of cellular processes, including development and
proliferation. Thus, STAT3 target genes are a reflection of the process
needed and are cell type specific. Figure 1 illustrates the signalling
pathways of IL-6.
Nearly every cell that expresses the signalling subunit gp130 can
respond to IL-6 via soluble IL-6 receptor (sIL-6R) released by
proteolytic cleavage of membrane-bound IL-6R14 or by translation
from an alternatively spliced messenger RNA. This is so called ‘trans-
signalling’.15 Trans-signalling provides a platform for multiple cells to
respond to IL-6 that would not otherwise be responsive to IL-6 itself.
That sIL-6R works as an agonist is therefore unusual. An exception to
the rule is that human osteoblasts have a high expression of
membrane-bound IL-6R, but cannot respond to IL-6 and
downstream signalling unless it is auto cleaved.16 The reason that
osteoblasts have such high levels of receptor expression, yet cannot
respond without cleavage of the IL-6R is unclear.16
SIL-6R SHEDDING AND REGULATION
Regulating the immune response is critical in halting aberrant
inflammation leading to unwanted tissue damage. One process of
negative feedback of the immune response in vivo is the liberation of
soluble cytokine receptors that lead to negation of soluble cytokine
signals. This provides a mechanism to prevent excessive immune
responses. However, the sIL-6R when bound to IL-6 is agonistic, not
antagonistic. The regulation of sIL-6R shedding from cells is through
two independent processes. The first mechanism of production of sIL-
6R is through ‘shedding’ via proteolytic cleavage of the membrane-
bound form of IL-6R mediated by a disintegrin and metalloprotease
17 (ADAM17) and to a lesser degree ADAM10.17–19 ADAM17 was
initially identified as the enzyme responsible for the liberation of
tumour necrosis factor-a. Purification of ADAM17 was based on
hydrolysis of tumour necrosis factor-a substrates. Another
mechanism of sIL-6R being released is through a splice variant.
This alternative splice variant lacks the transmembrane domain. It is
noteworthy that multiple diverse stimuli lead to cleavage and release
of sIL-6R from different cells including the phorbol ester phorbol-12-
myristate-12-acetate, a potent T-cell activator and mitogen.20
It is interesting that C-reactive protein itself can induce proteolytic
shedding of membrane IL-6R into a soluble receptor.21 It is known
that IL-6 stimulates the acute phase amount of C-reactive protein and
now this could work by then shedding the receptor to alter responsive
cells to facilitate wound healing.21 Therfore, IL-6 signalling may serve
to help the wound healing response, whatever the stimuli, but a
failure of resolution of IL-6 may yield pro-fibrotic pathways.
C-reactive protein is elevated in inflammatory fibrosing conditions,
including SSc, and correlates with many disease indices.22 Matthews
et al.14 showed that cholesterol depletion triggers membrane-bound
IL-6R shedding, and this is mediated via the ‘sheddase’ ADAM17 also
called TACE and to lesser degree ADAM10 and bacterial
metlloproteases induces IL-6R shedding.23 Interestingly, a recent
study using the bleomycin model of fibrosis demonstrated a
reduction in skin fibrosis when pretreated with TAPI, a chemical
inhibitor of ADAM17.24 This raises the posibilty that inhibition of
ADAM17 leads to reduced cleavage of sIL-6R and hence release of sIL-
R, and therefore less trans-signalling mediating fibrosis. A recent
paper using primary neutrophils demonstrated that apoptosis
(induced by a wide variety of chemical agents) induced IL-6R
Figure 1 IL-6 signalling and trans-signalling. Hepatocytes and leukocytes
including T and B cells express the IL-6R (a) and signal through what is
termed classic signalling as the cytokine IL-6 binds both the IL-6R and the
common shared subunit gp130, which leads to JAK activation and STAT3
phosphorylation and/or RAS/MAPK activation and to transcription of target
genes. The red indicates transcription factors. (b) Demonstration of trans-
signalling in all cells that do not express the IL-6R, but respond by the
binding of soluble IL-6R to IL-6 and gp130 and downstream signalling.
IL-6R can be shed from the cell membrane via the enzyme ADAM17/TACE
(yellow box) or through an alternative spliced IL-6R gene or to a lesser
degree ADAM10 can release IL-6R. Activation of T cells leads to shedding
of IL-6R from the membrane, which can then bind IL-6 and initiates
downstream signalling in the target cell. TACE, tumour necrosis factor-a-
converting enzyme.
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shedding mediated by apoptosis and was ADAM17-dependent, and
sIL-6R helped facilitate signalling in neighbouring non-apoptotic
cells.25 This suggests that apoptotic cells can facilitate a wound healing
phenotype by releasing sIL-6R thereby rendering local cells responsive
(that would otherwise not be) to IL-6 and the fibrotic response. In
other words, local cell dying switches the local microenvironment
from pro-inflammatory to a more wound healing environment
necessary to promote repair. It has been speculated in SSc apoptosis
of endothelial cells could act as a ‘triggering’ event in the early stages
of the disease.26 It is tempting to speculate that this endothelial
apoptosis leads to inflammation and the recruitment and retention of
mononuclear cells to the site of apoptosis, and that after the initial
inflammation the ‘spent’ leukocytes apoptose and release sIL-6R into
the local environment.
EVIDENCE FOR A ROLE OF IL-6 IN SSC
Multiple lines of evidence indicate that IL-6 is critical in SSc
pathogenesis.27 A recent study demonstrated that polymorphisms in
the IL-6 gene are important in susceptibility to SSc development.28
IL-6 is normally present in the blood at levels of 1–5 ng l1. IL-6 levels
are elevated in SSc,29 and also spontaneous production of IL-6 and
sIL-6R by peripheral blood leukocytes from SSc patients is elevated
compared with healthy controls.30 Furthermore, IL-6 levels predicted
worse outcome for SSc patients. Indeed as well as PBMCs that secrete
IL-6 it has been shown that epidermis stains very strongly for IL-6
and also fibroblasts in the dermis from SSc patients.22 However,
fibroblasts express negligible levels of IL-6R. We have found low
messenger RNA levels for the IL-6R in dermal fibroblasts and no
protein expression of IL-R. We also demonstrated that IL-6 trans-
signalling leads to elevated collagen synthesis, a marker of fibrosis.31,32
Interestingly, we also found that unmanipulated CD3þ T cells
secreted higher levels of sIL-6R in basal conditions from SSc donors
than T cells from controls, indicating both higher secretion basally
and activation of CD3þ T cells.32 Thus, trans-signalling appears to be
the dominant pathway utilised for collagen synthesis in dermal
fibroblasts. IL-6 levels have also been found to be elevated in
bronchoalveolar lavage fluid from patients with SSc. IL-6 levels also
correlate with the modified Rodnan skin score, hinting at a possible
causal relationship between the two variables.
In animal models of SSc, such as the bleomycin mouse model, IL-6
has been demonstrated to have a critical role in disease pathogen-
esis.27,33 The bleomycin animal model is inflammation driven and
requires leukocytes.34 Interestingly, mice treated with topoisomerase I
and Freund’s complete adjuvant developed autoimmunity, and
dermal fibrosis strikingly resembling SSc and genetic deletion of IL-
6 in this murine model of SSc reduced autoimmunity and subsequent
fibrosis. Interestingly, IL-6 deletion also altered the number and
frequency of Th17 cells induced in this model and increased
T-regulatory cells (Tregs). Saito et al.35 demonstrated a critical role
of IL-6 mediating the phenotype in the bleomycin model of SSc. They
used IL-6-KO mice and demonstrated reduced fibrotic changes
induced by bleomycin associated with reduced CCL3 levels. Indeed
fibroblasts isolated from idiopathic pulmonary fibrosis, a fibrotic
disease, were found to be proliferate in response to IL-6; however,
fibroblasts isolated from normal lungs and exposed to IL-6 showed
the opposite effect. This indicates that fibroblasts from the fibrotic site
have a fundamental aberration.
The relative contribution between IL-6 signalling and IL-6 ‘tran-
signalling’ may be important in disease pathogenesis. A recent paper
has used a monoclonal rat anti-mouse-IL-6 receptor antibody to
specifically inhibit trans-signalling in vivo after bleomycin treatment
to mimic SSc, and the authors found that there was an amelioration
of dermal fibrosis.36 The authors also found that in the anti-IL-6R-
treated bleomycin group along with reduced skin thickening also
decreased numbers of myofibroblasts expressing a-sma,36 suggesting
that blockade of sIL-R was the predominant mechanism mediating
reductions in myofibroblasts.
IL-6 can also rescue T cells from apoptosis, which would serve to
propagate the inflammatory insult in the tissue by increasing T-cell
numbers. Soluble gp130 is the natural negative regulator of IL-6
trans-signalling.37 It has no affinity for IL-6 or sIL-6R alone but binds
at high affinity for the IL-6/sIL-6R complex, thus is a negative
regulator.37 Elevated levels of sgp130 have been described in localised
SSc patient’s serum; this may reflect a negative feedback loop to
dampen IL-6 trans-signalling in this disease.
STAT-3 is the central downstream transcription factor activated by
IL-6 and this has been found to be highly activated in many
autoimmune diseases, including RA.38 Indeed, STAT3 is considered
a viable drug target in RA. We have recently demonstrated elevated
levels of STAT-3 in SSc-derived fibroblasts and preferential usage in
IL-6-dependent collagen production.31 Elevated phosphoSTAT-3 has
been demonstrated in skin biopsies from SSc patients.39 Furthermore,
blockade of JAK2, which lies upstream of STAT-3 in the bleomycin
model of SSc, reduced fibrosis in this model significantly,39 therefore
indicating the pivital role of the transcription factor STAT-3. We have
demonstrated using a small molecular inhibitor of STAT3 in vitro that
IL-6 trans-signalling leading to excessive collagen I messenger RNA
expression is STAT3 mediated; however, IL-13-mediated collagen I
gene expression is STAT3-independent. Indeed, genetic ablation of
STAT3 in mice protects mice from bleomycin-induced fibrosis.40
DIRECT FIBROTIC ACTIONS OF IL-6
Fibrosis is a pathological situation when the normal wound healing
response has become aberrant. IL-6 and fibrotic events may be
mediated directly via direct transcriptional activation of collagen or
through the upregulation of other cytokines that act in a autocrine
manner.41 In SSc, the primary issue is increased collagen deposition
and it has been shown that the addition of IL-6 to dermal fibroblasts
leads to upregulation of collagen.22,42 Indeed, IL-6 has been shown to
induce synthesis of collagen in human tendon.43 However, IL-6-KO
mice have a relatively mild phenotype likely indicating a level of
redundancy. In contrast, gp130-deleted mice die before birth, thus
underlying the importance of gp130 signalling. Gp130 has numerous
cytokines as its ligand. However, IL-6-KO mice do show a delayed
wound healing phenotype.44 In IL-6-KO mice, the delay in wound
healing after wounding is also accompanied by a reduction in
transforming growth factor-b1 (TGF-b1) expression. TGF-b1 is one
of the most potent fibrotic cytokines known and is associated with
multiple fibrotic diseases. Indeed, TGF-b1 is a key drug target in
fibrosis in general and mediates its effects primarily via the
transcription factor Smad3. Interestingly, differences in wound
healing between IL-6 total and IL-6R-KO mice were noted with IL-
6R-KO mice having less severe reduction in wound healing compared
with IL-6 KO as compared with control. It was also noted that in IL-
6R-deleted mice, phosphorylated extracellular signal-related kinase
was elevated, and this may be a compensatory mechanism as chemical
inhibition of MEK in the IL-6R-KO mice reduced wound closure
time. Extracellular signal-related kinase can be activated in response
to IL-6 in fibroblasts.22 In vitro cultures of dermal fibroblast cultured
with anti-IL-6 antibodies attenuated collagen I levels in dermal
fibroblasts derived from SSc donors compared with nonspecific
isotype-matched antibody.42 However, despite a large amount of
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research investigating this area, it is rather surprising that it is still
unknown at the molecular level how IL-6 leads to fibrosis and which
downstream signalling pathway contributes to this extracellular
matrix (ECM) deposition. Further examination of the signalling
nodes downstream of IL-6 receptor engagement may delineate this
pathway further and lead to novel anti-fibrotic therapeutics.
IL-6 AND TIMPS
In order to produce and maintain an appropriate ECM, there are
precise and specific tissue remodelling mechanisms present in the
body. These tissue remodelling mechanisms are co-ordinated by
specific sets of enzymes, such as matrix metalloproteinases (MMPs).
There are 24 MMPs present in mammals and they have a wide range
of functions, including the catabolism of the ECM. MMP function is
regulated by tissue inhibitors of metalloproteinases (TIMPs), which
are 25–31 kDa proteins and bind to the active site of MMP, at a 1:1
ratio, inhibiting their function. There are four TIMP proteins in
humans, and the ratio of TIMP and MMP is crucial in regulating the
turnover of ECM. Altering the TIMP–MMP ratio can lead to
pathological consequences as seen in diseases such as RA, SSc and
idiopathic pulmonary fibrosis. Animal models have highlighted the
importance in the maintenance of the TIMP–MMP ratio. Over-
expression of TIMP resulted in increased ECM deposition, particu-
larly an increase in collagen levels. Also, in a bleomycin lung fibrosis
mouse model, an elevated level of TIMPs is observed at the site of
lung fibrosis.45
Upon tissue damage, mononuclear cells infiltrate the site of injury
secreting a milieu of cytokines and chemokines polarising the healing
response. The composition of the cytokine milieu can change the
composition of MMP and TIMP in the tissue, thus affecting the ECM
composition. In SSc patient serum, elevated levels of TIMP-1 is
observed. Stimulation of fibroblasts with cytokines including IL-1b,
TGF-b and oncostatin M induces TIMP-1 expression. Of particular
interest oncostatin M, like IL-6, signals via the gp130 subunit
implicating a role of this signalling pathway in the induction of
TIMP-1 expression. Indeed, IL-6 trans-signalling was shown to induce
TIMP-1 production in synovial fibroblasts.46 IL-6 has also been
shown to induce TIMP-1 production in synovial cells, chondrocytes
and endothelial cells. This IL-6 induction of TIMP-1 has shown to be
STAT3 dependent as transfection of a dominant-negative mutant of
STAT3 abolished IL-6-induced TIMP-1 expression in hepatocellular
cells.
The AP-1 transcription factor, JunD, binds to the AP-1-binding site
and induces TIMP-1 and IL-6 expression in rat hepatic stellate cells.47
Overexpression of JunD has been shown to induce TIMP-1 and IL-6
production.47 Thus, it is possible that in SSc ligands that induce JunD
expression may be elevated in SSc patients leading to the induction of
IL-6 and TIMP-1 expression.
IL-6 AND TH17 CELLS IN SSC
The differentiation of naı¨ve CD4þ T cells into effector cells begins
with activation of the T-cell receptor, and specific cytokines polarise
the cell to a particular T-cell lineage. The exact T-effector cell is
determined by a number of factors but the local cytokine environ-
ment appears particularly important. However, the identification of
IL-17A/F and that IL-17A/F producing T-helper cells were a unique
cell subset forced us to look outside the Th1/Th2 paradigm. Th1 cells
produce IFN-g and Th2 cells that produce IL-4, IL-5, TGF-b and IL-
13 and help clear extracellular pathogens.48 Th17 cells are a distinct
class of effector T cells, characterised by high IL-17A expression.
These Th17 cells are a class of effector T cells that can be polarised by
a distinct set of cytokines and have ascribed to them specific
transcription factors like retinoid-related orphan receptor gamma t.
The transcription factor STAT3 (itself a target of IL-6) is also
necessary for the generation of Th17 cells. IL-17 has intense pro-
inflammatory effects and has been associated with a variety of
autoimmune diseases, including RA. High frequencies of IL-17
T cells have been reported in RA and multiple sclerosis. Indeed, IL-
17 gene-deleted mice are collagen-induced arthritis suppressed,
suggesting a critical role of IL-17 in RA. The differentiation of
Th17 cells from naı¨ve T cells requires both IL-6 and TGF-b, both
cytokines are elevated in SSc.49 Indeed in the absence of IL-6 and
presence of TGF-b, FOXP3þ Treg cells are polarised and help
maintain self-tolerance.50 However, in the presence of both TGF-b
and IL-6, pathogenic pro-inflammatory Th17 cells predominate,
indeed IL-6-KO mice have a deficit in production of Th17 cells.51
These Th17-deficient mice also are resistant to the development of
experimental autoimmune encephalitis, a model of MS, thus
demonstrating the critical role of IL-6 in Th17 induction and
autoimmunity.51
In SSc, pathogenic Th17 cells have been found to be altered in the
peripheral blood of patients compared with healthy controls.52
Increased serum IL-17 levels have also been observed in SSc
compared with both healthy controls and SLE patients. And
although there is an increased frequency of Treg cells in SSc
patients, they are functionally compromised53 as demonstrated with
functional Treg assays. Tregs are natural (or inducible) populations of
T cells that influence the immune response and control the
development of autoimmunity. We have also found that Tregs
produce much lower levels of IL-10 in SSc patients compared with
controls at the same time as elevated levels of T cell-derived IL-6.31
Th17 subset also produce the cytokine IL-22 and this has been found
to be elevated in the lesional skin of SSc patients.54 As the cytokine
milieu at the local site of induction of T-cell polarisation determines
the distinct subset of T-effector cells, the overall balance between pro-
inflammatory IL-6 and immune-modulating TGF-b determine the
polarisation of naı¨ve T cells toward a Th17 or Treg effector subset,
thus targeting IL-6 would lead to suppression of deleterious IL-17-
producing T cells while at the same time increasing the number of
‘good’ Treg cells.
IL-6 AND FIBROBLASTS
Trans differentiation of cardiac fibroblasts to the pathogenic myofi-
broblasts mediated by IL-6 has been reported.55 In a rat model of
cardiac hypertrophy by artery ligation, collagen synthesis and
hypertrophy occurs but inhibition of IL-6 or specific inhibition of
STAT3 phosphorylation resulted in blockade of fibrosis and
hypertrophy.56 This was also shown in in vitro cultures,56 suggesting
that IL-6-mediated collagen synthesis is driving the fibrosis and
hypertrophy seen in this model. Indeed SSc fibroblasts have elevated
STAT3 phosphorylation constitutively compared with controls. It has
recently been demonstrated that cardiac fibrosis induced by
angiotensin II infusion in mice leads to IL-6-dependent fibrosis
through activation of the pro-fibrogenic molecule TGF-b leading to
collagen deposition mediated through Smad3 phosphorylation and
activation.57
CONCLUSION
IL-6 is a pleiotropic cytokine whose aberrant expression is associated
with a variety of diseases, including RA, Castleman’s disease and
osteoporosis. Its role in SSc pathogenesis is now only beginning to be
elucidated. It is well documented that IL-6 levels are elevated in SSc
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serum and also localised in skin biopsies, it is especially prominent in
early stages of disease. Moreover, IL-6 levels correlate tightly with skin
thickness scores indicating a casual relationship. This gives a rationale
for the targeting of IL-6 in this disease setting. To date, there is no
study looking at serum levels of IL-6R in relation to duration of
disease or subtype. Tocilizumab is a monoclonal antibody against the
IL-6 receptor, which is very effective in RA, Castleman’s disease and
juvenile idiopathic arthritis.58 It has been well tolerated and the safety
profile is excellent. In a case report from Japan, two patients treated
with tocilizumab showed a small improvement in skin score
thickening.59 They also showed a reduction in tissue collagen
levels.59 This was only a small study; however, and a placebo-
controlled clinical trial is needed to corroborate these findings. It is
worth bearing in mind that SSc has no effective treatment and is an
unmet clinical need.
Sirukumab is another monoclonal IL-6 antibody that targets only
soluble IL-6 and not the receptor, and should only target the
‘classical’ pathway of IL-6 and not so called ‘transsignalling’. This
has been shown to be safe and well tolerated; however, no published
data are available on the efficacy. Clinical trials are ongoing
investigating this in RA. Thus, we can compare the efficacy between
the canonical and non-canonical pathway in IL-6 signalling. If trans-
signalling is the primary pathological hallmark in the disease, one
would expect tocilizumab to have a greater clinical effect. The clinical
benefits of anti-IL-6 treatment may be twofold: directly blocking the
clear pro-fibrotic nature of IL-6 in fibroblasts and also blocking the
inflammation part of SSc through the reduction of the polarisation
of pathogenic Th17 cells and the upregulation of the tolerance
Treg cells.
The reduction of sIL-6R through the neutralisation with tocilizu-
mab has been a clinical breakthrough in the treatment of RA.58 We
postulate that marked improvements in clinical status should be seen
with tocilizumab in SSc. However, blockade together with other pro-
fibrotic cytokines, such as IL-13 (lebrikizumab) or IL-4, may yield
greater clinical responses. A current clinical trial assessing tocilizumab
in SSc is underway.
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